These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

391 related items for PubMed ID: 11656915

  • 1. IRBs and randomized clinical trials.
    Meinert CL.
    IRB; 1998; 20(2-3):9-12. PubMed ID: 11656915
    [No Abstract] [Full Text] [Related]

  • 2. Multicenter trials and subject eligibility: should local IRBs play a role?
    Freedman B.
    IRB; 1994; 16(1-2):1-6. PubMed ID: 11652320
    [No Abstract] [Full Text] [Related]

  • 3. Toward a more comprehensive approach to protecting human subjects: the interface of data safety monitoring boards and institutional review boards in randomized clinical trials.
    Gordon VM, Sugarman J, Kass N.
    IRB; 1998; 20(1):1-5. PubMed ID: 11655324
    [No Abstract] [Full Text] [Related]

  • 4. Continuing review of research involving human subjects: approach to the problem and remaining areas of concern.
    Gordon B, Prentice E.
    IRB; 1997; 19(2):8-11. PubMed ID: 11655323
    [No Abstract] [Full Text] [Related]

  • 5. IRB review of adverse events in investigational drug studies.
    Prentice ED, Gordon B.
    IRB; 1997; 19(6):1-4. PubMed ID: 11656910
    [No Abstract] [Full Text] [Related]

  • 6. IRB review of a Phase II randomized clinical trial involving incompetent patients suffering from severe closed head injury.
    Prentice ED, Antonson DL, Leibrock LG, Kelso TK, Sears TD.
    IRB; 1993; 15(5):1-7. PubMed ID: 11659703
    [No Abstract] [Full Text] [Related]

  • 7. Ethical and legal considerations in dental caries research involving human subjects.
    Branson R.
    J Dent Res; 1980 Jul; 59(Special Issue C):1214-364. PubMed ID: 11651755
    [No Abstract] [Full Text] [Related]

  • 8. The IRB's role in assessing the generalizability of non-NIH-funded clinical trials.
    Weijer C.
    IRB; 1998 Jul; 20(2-3):1-5. PubMed ID: 11656912
    [No Abstract] [Full Text] [Related]

  • 9. IRBs and pharmaceutical company funding of research.
    Jellinek MS, Levine RJ.
    IRB; 1982 Oct; 4(8):9-10. PubMed ID: 11651693
    [No Abstract] [Full Text] [Related]

  • 10. The changing clinical trials scene: the role of the IRB.
    Mitchell SC, Steingrub J.
    IRB; 1988 Oct; 10(4):1-5. PubMed ID: 11650078
    [No Abstract] [Full Text] [Related]

  • 11. Human experimentation: the review process in practice.
    Cowan DH.
    Case West Reserve Law Rev; 1975 Oct; 25(3):533-64. PubMed ID: 11661165
    [No Abstract] [Full Text] [Related]

  • 12. IRBs and epidemiologic research: how inappropriate restrictions hamper studies.
    Cann CI, Rothman KJ.
    IRB; 1984 Oct; 6(4):5-7. PubMed ID: 11649562
    [No Abstract] [Full Text] [Related]

  • 13. An update on the PEG-SOD study involving incompetent subjects: FDA permits an exception to informed consent requirements.
    Prentice ED, Antonson DL, Leibrock LG, Prabhu VC, Kelso TK, Sears TD.
    IRB; 1994 Oct; 16(1-2):16-8. PubMed ID: 11652322
    [No Abstract] [Full Text] [Related]

  • 14. Changing federal regulation of IRBs, Part III: social research and the proposed DHEW regulations.
    Gray BH.
    IRB; 1980 Jan; 2(1):1-5+. PubMed ID: 11661793
    [No Abstract] [Full Text] [Related]

  • 15. Selective review of external adverse events: one IRB's response to the avalanche of IND safety reports.
    Gordon B, Prentice E.
    IRB; 1999 Jan; 21(3):10-1. PubMed ID: 11657877
    [No Abstract] [Full Text] [Related]

  • 16. Half-full or half-empty? Evaluating IRB performance.
    Mishkin B, Ariand N.
    Prof Ethics Rep; 1998 Jan; 11(3):4-7. PubMed ID: 11657925
    [No Abstract] [Full Text] [Related]

  • 17. Annual review: observed deficiencies and suggested corrections.
    Adams MS, Conrad DA.
    IRB; 1996 Jan; 18(6):1-4. PubMed ID: 11654743
    [No Abstract] [Full Text] [Related]

  • 18. Protecting research subjects after consent: the case for the "research intermediary.
    Reiser SJ, Knudson P.
    IRB; 1993 Jan; 15(2):10-1. PubMed ID: 11651567
    [No Abstract] [Full Text] [Related]

  • 19. An IRB member's perspective on access to innovative therapy.
    Moore DL.
    Albany Law Rev; 1994 Jan; 57(3):559-81. PubMed ID: 11652854
    [No Abstract] [Full Text] [Related]

  • 20. Commission says institutional review boards should change procedures now.
    Maloney DM.
    Hum Res Rep; 1999 Jan; 14(1):1-2. PubMed ID: 11657555
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.